The Transgenic &Targeting Core Facility is the sole service generating genetically modified mice for the Case CCC and the Cleveland Biomedical community. The services offered are the generation of transgenic and knockout mice, rederivations, in vitro fertilization, generation of chimeric mice, and the design and construction of DNA vectors. The Core began to offer sperm cryopreservation for inbred strains in 2009. The Core provides consultation on scientific, technical and practical matters of mouse genetics. It is the only Transgenic facility in the Cleveland area, and serves investigators at CWRU, University Hospitals, Cleveland Clinic, the VA Hospital, MetroHealth Medical Center, and Kent State University. The facility operates on a fee-for-service basis, and provides consultation with all services. The facility supports the Case CCC mission through the generation of mouse models of cancer, and tools and materials for investigation of basic science questions. The Core is formally accessible by all members of the Case CCC. The Transgenic &Targeting Core Facility is competitive with transgenic cores at other academic institutions in success rates, turnaround, and pricing. As a local service, it has advantages for cancer investigators by direct access to consultation and training, better pricing of services, and control of mouse pathogens. The Core has helped a number of labs with minimal or no experience transition into mouse genetic research programs. In the last funding period the Core has assisted Cancer Center members in: generating mice that model human mutations leading to cancer;identifying cancer susceptibility loci;generating mice for in vivo imaging of tumors;and investigating the basic biology of genes implicated in cancer. Since 2007, Cancer Center members have published 23 peer-reviewed papers with transgenic or knockout mice generated by the facility, and since 2004, transgenic or gene targeted mice created by the Core have been featured in 36 publications by Case CCC members.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182|
|Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266|
|Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:|
|Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151|
|Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231|
|Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903|
|Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376|
|Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237|
|Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601|
|Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643|
Showing the most recent 10 out of 1227 publications